In addition, several studies linked CAFs to a poor prognosis in ovarian cancer patients, as they increase resistance to platinum-based drugs and accelerate tumor reoccurrence via upregulation of fibroblast activation protein alpha (FAP), which ultimately promotes tumor cell proliferation, invasion and migration via its gelatinase activity (Mhawech-Fauceglia et al., 2015). This evidence concerns the gene FAP and ovarian cancer.